NCT06017037

REward Processing And Citalopram Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Oxford · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of this experimental medicine study is to examine the effect of increasing serotonin on reward processing in healthy volunteers. The main questions it aims to answer are: 1. Does a subacute increase in serotonin influence the activation regions during reward learning 2. Does a subacute increase in serotonin influence behavioural markers of reward valuation (effort task), responsiveness (taste task) and learning (learning task) Participants will be: given a 7-day course of the selective serotonin reuptake inhibitor, citalopram. undergo behavioural testing complete a reward learning task whilst undergoing fMRI Researchers will compare results against a placebo group.

Conditions

• Anhedonia

Interventions

Type	Name	Description
DRUG	Citalopram 20mg	Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
DRUG	Placebo	Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days

Timeline

• Start date: 2023-05-19
• Primary completion: 2024-05-01
• Completion: 2024-05-01
• First posted: 2023-08-30
• Last updated: 2023-08-30

Locations

1 site across 1 country: United Kingdom